Pinned Tweet
New publication 📢
Very exciting news about Nivo for HL over the last months, unfortunately its access is still troubling in LATAM. Here we report our center's experience with reduced doses of Nivo in r/r HL
✅73% ORR
✅43% CR
link.springer.com/article/10…
Perla Colunga retweeted
Cofepris autoriza el primer ensayo clínico en México con células CAR-T de manufactura nacional, desarrollado por la Universidad Autónoma de Nuevo León (UANL). 🔬🇲🇽
Tras una rigurosa evaluación científica, técnica y ética, autorizamos el protocolo que se llevará a cabo de manera integral en el Hospital Universitario “Dr. José Eleuterio González”: obtención, modificación genética y administración celular en personas adultas con leucemia linfoblástica aguda recidivante o refractaria.
Con esta acción, también se sientan nuevas bases normativas para el desarrollo seguro de terapias avanzadas y consolida la capacidad de investigación científica nacional. ⚖️📋
Ver detalles: gob.mx/cofepris/articulos/co…
#Cofepris #UANL #EnsayosClínicos #TerapiasAvanzadas #SaludPública #RegulaciónSanitaria #CélulasCART
Perla Colunga retweeted
Con orgullo mostramos nuestro consenso LATAM de linfoma T. Esperemos que esta guía ayude a nuestros colegas. @lymphomahub @Grupo_GELL @lymphoma @LymphomaActio @DrRaulCordoba
Perla Colunga retweeted
🚨 HOT OFF THE PRESS!!
Mapping the capacity for geriatric blood Cancer Care in Latin America: A cross-sectional survey of current status and future priorities
Outstanding leadership of @PerlaRcp in this project of #hematology & #geriheme in LatAm
share.google/mhI5AJ1MYtcDamb…
Perla Colunga retweeted
Our Real-world paper about plasmablastic lymphoma is out ! Kudos @HumbertoMar_Cor @GELL01433166 @Grupo_GELL . One of the largest series published.
Perla Colunga retweeted
Beyond excited to receive @TheEBMT Outreach Travel Grant for the ITCT🥳
Many thanks for all the support to @TheEBMT and my mentors 🙌🏾 @morcossandino @PerlaRcp
See you in Barcelona! 🇪🇸
Perla Colunga retweeted
Please welcome Astrid Pavlovsky as the incoming co-Chair of @WomenInLymphoma alongside Anna Sureda.
In this video, Astrid shares her vision for the future, the values that drive the community, and what’s coming next.
Perla Colunga retweeted
Excited to share our systematic review and meta-analysis on early GVHD prophylaxis in haploidentical HSCT and its potential role in reducing CRSA. Early immunosuppression showed promising results, but prospective studies are still needed. Always happy to work with the best team
Perla Colunga retweeted
🚨 ¡Comienza la Serie 18 en Español de WiL!
🗓 6 mayo 2026
🎓 Diagnóstico en linfomas no Hodgkin: lo clave en la práctica clínica
👩⚕️ Dra. Marcela de Dios Soler + Dra. Leticia Quintanillas
🔗 Sumate: #Linfoma #Hematología #WiL
Perla Colunga retweeted
Coming soon: #WiLingWednesdays Series 18 – LATAM Series
Free educational webinars in Spanish featuring global experts, with a special focus on Latin America
📅 May–June 2026
🌍 Women in Lymphoma: one global community, one shared purpose 💜
Perla Colunga retweeted
Transplant is very hard to implement in LMICs.
We have done it through hard work, creativity, clinical research and institutional support.
Fact accredited, now working hard to implement #CARTcells.
The @TheEBMT made a video about our transplant program. Watch it here:
youtube.com/watch?v=_OVxFYPt…
Perla Colunga retweeted
In the US we argue CAR-T vs bispecifics while 36% of Latin America fights for access to rituximab.
Let that sink in.
GELL Survey 2025 — 73 centers, 16 countries:
73% highly restricted access to bispecifics
~0% commercial CAR-T outside Brazil
Only 15% have NGS
Only 35% access to clinical trials
We’re having 2026 debates with early 2000s access.
The real question isn’t CAR-T vs bispecifics. It’s: how do we close this gap?
Sobering data presented by @DrMCanales here in Chile. @LymphomaEx
Colunga-Pedraza et al. Blood 2025;146(Suppl 1):6193
#Lymphoma #DLBCL #LATAM #GlobalOncology #HealthEquity
Perla Colunga retweeted
Danazol treatment for poor graft function after hematopoietic stem cell transplantation: a single centre experience @BMTjournal
nature.com/articles/s41409-0…
Perla Colunga retweeted
Mentorship and Community at the Women in Lymphoma Meeting - Perla Colunga (@PerlaRcp)
@WomenInLymphoma @DrCarlaCasulo
oncodaily.com/voices/428764
#OncoDaily #Oncology #Cancer #Health #Medicine
One week ago at #ASH25, the Women in Lymphoma meeting @WomenInLymphoma . Grateful for the opportunity to receive mentorship from @DrCarlaCasulo. Already looking forward to 2026.
Perla Colunga retweeted
Important conclusions were drawn from this study:
1. There's a gigantic room for improvement in outcome definition, selection, and implementation in ITP clinical trials
2. Friendship and brightly kind mentorship are a great motor for science
Happy for this incredible humans
Perla Colunga retweeted
So privileged to share office, laughs, friendship, ideas, work, advice, worries, victories, and every single up and down with these two incredible women
Thanks for being such an exemplary role model and mentor @PerlaRcp
HBD Ale!! Always better to do science with a great friend
Couldn’t agree more 👁️
Trainees beware🚨Meetings like #ASH25 are high-density environments of social validation and external rewards.
Extrinsic goals provide temporary satisfaction, undermine autonomy and have negative psychological effects!
Instead focus on intrinsic goals like personal growth, relationships, and community contribution, you will be proud and need no applause.
Happy to share our work #ASH25, in collaboration with @GELL_Group!
Lymphoma care has advanced — but access remains unequal.
70+ Latin America centers:
-Limited access to clinical trials
-CAR-T in only 8%
-Novel therapies highly restricted
Closing these gaps must be a priority
